Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$24.2 million.

  • Taysha Gene Therapies' Cash from Operations fell 1180.2% to -$24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.7 million, marking a year-over-year decrease of 713.87%. This contributed to the annual value of -$81.2 million for FY2024, which is 1123.97% down from last year.
  • Taysha Gene Therapies' Cash from Operations amounted to -$24.2 million in Q3 2025, which was down 1180.2% from -$20.2 million recorded in Q2 2025.
  • Taysha Gene Therapies' Cash from Operations' 5-year high stood at $14.7 million during Q4 2022, with a 5-year trough of -$40.9 million in Q1 2022.
  • Moreover, its 4-year median value for Cash from Operations was -$20.2 million (2023), whereas its average is -$20.6 million.
  • Over the last 5 years, Taysha Gene Therapies' Cash from Operations had its largest YoY gain of 5069.49% in 2023, and its largest YoY loss of 20955.0% in 2023.
  • Over the past 4 years, Taysha Gene Therapies' Cash from Operations (Quarter) stood at $14.7 million in 2022, then tumbled by 209.55% to -$16.1 million in 2023, then dropped by 13.59% to -$18.3 million in 2024, then crashed by 32.0% to -$24.2 million in 2025.
  • Its Cash from Operations stands at -$24.2 million for Q3 2025, versus -$20.2 million for Q2 2025 and -$22.0 million for Q1 2025.